SCHEMBL16888494

SCHEMBL16888494

C=C(C)c1cnc(-c2cc(Cl)ccc2F)cc1Nc1ncncc1C(=O)NC[C@H](C)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 20/20 1.00
ACVR1B P36896 19/20 1.00
ACVRL1 P37023 14/20 1.00
ACVR1 Q04771 3/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16879640 1.00 TGFBR1 (1.00) TGFBR1ACVR1BACVRL1ACVR1
SCHEMBL22270342 0.90 TGFBR1 (0.81) TGFBR1ACVR1BACVRL1ACVR1
SCHEMBL16879264 0.89 TGFBR1 (1.00) TGFBR1ACVR1BACVRL1ACVR1
SCHEMBL16879467 0.89 TGFBR1 (1.00) TGFBR1ACVR1BACVRL1ACVR1
SCHEMBL16879744 0.88 TGFBR1 (1.00) TGFBR1ACVR1BACVRL1ACVR1
SCHEMBL16879742 0.88 TGFBR1 (1.00) TGFBR1ACVR1BACVRL1ACVR1
SCHEMBL16888478 0.86 TGFBR1 (0.76) TGFBR1ACVR1BACVRL1ACVR1
SCHEMBL18219798 0.86 TGFBR1 (0.79) TGFBR1ACVR1BACVRL1ACVR1
SCHEMBL20397410 0.86 TGFBR1 (0.79) TGFBR1ACVR1BACVRL1ACVR1
SCHEMBL16888454 0.86 TGFBR1 (0.76) TGFBR1ACVR1BACVRL1ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11702401-B2 Compounds and methods of use MEDIVATION TECHNOLOGIES LLC (US) 2023-07-18 US disclosed
US-11702401-B2 Compounds and methods of use MEDIVATION TECHNOLOGIES LLC (US) 2023-07-18 US disclosed
US-11702401-B2 Compounds and methods of use MEDIVATION TECHNOLOGIES LLC (US) 2023-07-18 US disclosed
US-20220000847-A1 Compounds and Methods of Use MEDIVATION TECHNOLOGIES LLC (US) 2022-01-06 US disclosed
US-20220000847-A1 Compounds and Methods of Use MEDIVATION TECHNOLOGIES LLC (US) 2022-01-06 US disclosed
US-11053216-B2 Compounds and methods of use MEDIVATION TECHNOLOGIES LLC (US) 2021-07-06 US disclosed
US-11053216-B2 Compounds and methods of use MEDIVATION TECHNOLOGIES LLC (US) 2021-07-06 US disclosed
EP-3089971-B1 COMPOUNDS AND METHODS OF USE MEDIVATION TECH LLC (US) 2020-07-29 EP disclosed
EP-3089971-B1 COMPOUNDS AND METHODS OF USE MEDIVATION TECH LLC (US) 2020-07-29 EP disclosed
US-20200071296-A1 Compounds and Methods of Use MEDIVATION TECHNOLOGIES LLC 2020-03-05 US disclosed
US-20180208577-A1 Compounds and Methods of Use MEDIVATION TECHNOLOGIES LLC 2018-07-26 US disclosed
US-20180208577-A1 Compounds and Methods of Use MEDIVATION TECHNOLOGIES LLC 2018-07-26 US disclosed
US-20180208577-A1 Compounds and Methods of Use MEDIVATION TECHNOLOGIES LLC 2018-07-26 US disclosed
US-10030004-B2 Compounds and methods of use MEDIVATION TECHNOLOGIES LLC (US) 2018-07-24 US disclosed
US-10030004-B2 Compounds and methods of use MEDIVATION TECHNOLOGIES LLC (US) 2018-07-24 US disclosed
US-10030004-B2 Compounds and methods of use MEDIVATION TECHNOLOGIES LLC (US) 2018-07-24 US disclosed
US-20160326137-A1 Compounds and Methods of Use MEDIVATION TECHNOLOGIES LLC 2016-11-10 US disclosed
US-20160326137-A1 Compounds and Methods of Use MEDIVATION TECHNOLOGIES LLC 2016-11-10 US disclosed
US-20160326137-A1 Compounds and Methods of Use MEDIVATION TECHNOLOGIES LLC 2016-11-10 US disclosed
WO-2015103355-A1 COMPOUNDS AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2015-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000847-A1 Compounds and Methods of Use TGFB2, TGFB1, HDGF TGFBR1 13/4885ACVR1B 150/4885ACVRL1 197/4885
US-11702401-B2 Compounds and methods of use TGFB2, TGFB1, HDGF TGFBR1 13/4885ACVR1B 150/4885ACVRL1 197/4885
US-10030004-B2 Compounds and methods of use TGFB2, TGFB1, HDGF TGFBR1 13/4885ACVR1B 150/4885ACVRL1 197/4885
US-20160326137-A1 Compounds and Methods of Use TGFB2, TGFB1, HDGF TGFBR1 13/4885ACVR1B 150/4885ACVRL1 197/4885
US-20200071296-A1 Compounds and Methods of Use TGFB2, TGFB1, HDGF TGFBR1 13/4885ACVR1B 150/4885ACVRL1 197/4885
US-11053216-B2 Compounds and methods of use TGFB2, TGFB1, HDGF TGFBR1 13/4885ACVR1B 150/4885ACVRL1 197/4885
US-20180208577-A1 Compounds and Methods of Use TGFB2, TGFB1, HDGF TGFBR1 13/4885ACVR1B 150/4885ACVRL1 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.